Ozempic and other GLP-1 drug settlement values are projected from roughly $50,000 to $700,000 per plaintiff, with the highest amounts for severe gastroparesis (stomach paralysis) requiring hospitalization or surgery. This Ozempic and GLP-1 settlement calculator estimates a payout from your injury-severity tier, medical bills, lost wages, and a pain-and-suffering multiplier. The cases are consolidated in the federal GLP-1 multidistrict litigation (MDL 3094) before the U.S. District Court for the Eastern District of Pennsylvania. Use the calculator, then read how the alleged injuries, the MDL, and damages combine to set GLP-1 payouts.
Ozempic, Wegovy, Mounjaro, Rybelsus, and similar GLP-1 receptor agonists are used to treat type 2 diabetes and obesity. Plaintiffs allege the manufacturers (Novo Nordisk and Eli Lilly) failed to adequately warn of risks including severe gastroparesis, intestinal blockage (ileus), and, in some claims, a form of sudden vision loss called NAION (non-arteritic anterior ischemic optic neuropathy).
Because GLP-1 litigation is new and no settlement matrix exists, any estimate is speculative. Projected values combine an injury-severity tier with conventional damage math, with the most severe gastrointestinal injuries anchoring the highest tiers. The calculator follows this approach:
GLP-1 Estimate = Injury-Severity-Tier Anchor + Economic Damages (medical + lost wages) + Pain & Suffering (medical × multiplier)
Severe gastroparesis requiring hospitalization, a feeding tube, or surgery anchors the top tier. Gastroparesis or bowel obstruction with ongoing care anchors the middle tier. NAION vision loss or other serious GI injury, and moderate treated injuries, anchor lower tiers. Medical records establishing the diagnosis and connecting it to GLP-1 use are central.
| Tier | Injury Profile | Projected Range |
|---|---|---|
| Tier 1 | Severe gastroparesis, hospitalization, surgery | ~$400,000 – $700,000 |
| Tier 2 | Gastroparesis or bowel obstruction, ongoing care | ~$150,000 – $400,000 |
| Tier 3 | NAION vision loss / serious GI injury | ~$75,000 – $250,000 |
| Tier 4 | Moderate injury, treated | ~$50,000 – $120,000 |
In February 2024, the Judicial Panel on Multidistrict Litigation centralized the GLP-1 cases into MDL 3094 before Judge Gene Pratter (later reassigned) in the Eastern District of Pennsylvania. The litigation covers semaglutide drugs (Ozempic, Wegovy, Rybelsus) and tirzepatide drugs (Mounjaro, Zepbound), with claims focused on gastroparesis and intestinal injuries; some plaintiffs added NAION vision-loss claims after a 2024 study suggested an association. A central battleground is general causation — whether the science establishes that these drugs cause the alleged injuries. As of 2026 the litigation remained in early stages, and the outcome of the causation fight will heavily influence whether and how cases resolve.
Suppose a patient who developed severe gastroparesis requiring hospitalization and a feeding tube (Tier 1) has $120,000 in medical bills, $50,000 in lost wages, and a pain-and-suffering multiplier of 3. The calculator computes economic damages of $170,000 and pain-and-suffering of $360,000 (medical × 3), for a formula value of $530,000 within the Tier 1 band, with a likely range near $291,500 to $795,000. Because the causation fight is unresolved, the actual outcome is uncertain. A Tier 3 NAION vision-loss claim with $40,000 in medical bills and a multiplier of 2.5 would land near that tier's anchor.
Under IRS Publication 4345, compensatory damages for a personal physical injury or sickness are generally excluded from taxable income. Interest and punitive damages are taxable, and amounts allocated to non-physical claims may be treated differently. Confirm the tax treatment of any specific recovery with a qualified professional.
A GLP-1 claim begins with medical records diagnosing severe gastroparesis, ileus, bowel obstruction, or NAION vision loss, plus pharmacy records proving drug use. The case is filed into MDL 3094 in the Eastern District of Pennsylvania, joining others for coordinated discovery. Unlike more mature mass torts, the GLP-1 litigation must first resolve general causation — whether the scientific evidence establishes that these drugs cause the alleged injuries. The court holds hearings and rulings on that threshold question, and only cases that survive proceed toward bellwether trials. Any settlement framework would follow favorable causation rulings and verdicts, with claims tiered by injury severity. This makes GLP-1 a longer and more uncertain process than usual.
GLP-1 cases are handled on contingency, with the attorney earning a percentage of any recovery (commonly 33% to 40%) plus case costs, which can be high because of the expert science needed on causation. Health insurers, Medicare, or Medicaid may assert liens for the treatment of gastrointestinal injuries, repaid from the settlement but often negotiable. This calculator estimates a gross value; the net is what remains after fees, costs, and liens. On a $500,000 gross GLP-1 settlement with a 40% fee, $20,000 in costs, and a $25,000 negotiated lien, the net would be roughly $255,000. Request a written disbursement statement.
The decisive uncertainty is general causation: if the court finds the science does not establish that GLP-1 drugs cause the alleged injuries, many cases could be dismissed. A short duration of use, a diagnosis with alternative causes (diabetes itself can cause gastroparesis), or sparse records all weaken a claim. The NAION vision-loss theory is newer and less settled than the gastroparesis theory. Because no settlement matrix existed as of 2026 and causation remained contested, all values are projections. Never stop a prescribed GLP-1 medication over the lawsuit; discuss any side effects with your doctor.
This Ozempic and GLP-1 settlement calculator is built for patients who used a GLP-1 receptor agonist — Ozempic, Wegovy, Rybelsus, Mounjaro, or Zepbound — for diabetes or weight loss and were diagnosed with severe gastroparesis (stomach paralysis), intestinal blockage (ileus), bowel obstruction, or, in some claims, NAION sudden vision loss. It is most relevant to those who required hospitalization, a feeding tube, or surgery, and to families pursuing claims after a catastrophic outcome. Because the litigation hinges on an unresolved general-causation fight, the tool is best treated as an educational illustration. Patients should never stop a prescribed GLP-1 drug over the lawsuit and should discuss any side effects with their doctor while seeking a case review.
The key points for GLP-1 claims are these. Injury severity sets the tier, with severe gastroparesis requiring hospitalization or surgery anchoring the top. General causation — whether the science proves these drugs cause the alleged injuries — is the decisive, unresolved question, and many cases could rise or fall on the court's rulings. The cases are consolidated in MDL 3094 in Pennsylvania, centralized in 2024, with no settlement matrix as of 2026. The gross estimate is reduced by attorney fees, costs, and liens. And because diabetes itself can cause gastroparesis, distinguishing the drug as the cause is critical. Treat every figure as a projection and let qualified counsel evaluate your diagnosis, drug history, and timeline.
This is emerging litigation, so figures are projections. Analysts commonly cite a range of about $50,000 to $700,000, with the highest amounts (often cited as $400,000-$700,000) for severe gastroparesis requiring hospitalization or surgery. No global settlement had been finalized as of 2026, and the outcome depends heavily on a pending general-causation fight over whether the science links the drugs to the injuries.
The core claims involve severe gastroparesis (stomach paralysis), intestinal blockage (ileus), and bowel obstruction allegedly caused by GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Rybelsus. Some plaintiffs added NAION (a form of sudden vision loss) claims after a 2024 study suggested an association. Plaintiffs allege the manufacturers failed to adequately warn of these risks.
MDL 3094 is the federal GLP-1 multidistrict litigation centralized in February 2024 in the U.S. District Court for the Eastern District of Pennsylvania. It consolidates cases involving semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) for coordinated pretrial proceedings, including a central fight over general causation.
Generally, patients who used a GLP-1 drug and were diagnosed with severe gastroparesis, intestinal blockage, bowel obstruction, or (in some claims) NAION vision loss may qualify. Documented drug use and a clear diagnosis are important. Because the litigation hinges on causation, an attorney evaluates whether your records and timeline fit the current criteria and deadlines.
No — do not stop a prescribed medication based on a lawsuit. GLP-1 drugs treat serious conditions like diabetes and obesity, and stopping can have health consequences. Discuss any side effects or concerns with your prescribing doctor, who can weigh the risks and benefits for your situation.
Under IRS Publication 4345, compensatory damages for a physical injury or sickness are generally not taxable. Interest and punitive damages are taxable, and non-physical-injury portions may be treated differently. Confirm the treatment of any specific payout with a tax professional.
As of 2026, MDL 3094 was in early stages, with general causation — whether the science proves the drugs cause the injuries — being litigated first. A settlement framework typically follows favorable causation rulings and bellwether trials. Mass-tort timelines often run several years, and the GLP-1 outcome is more uncertain than usual because the causation question is unresolved.